Axogen, Inc. (AXGN)

$5.06

+0.06

(+1.2%)▲

Market is closed - opens 7 PM, 29 Sep 2023

Insights on Axogen, Inc.

  • Increasing Revenue

    Revenue is up for the last 3 quarters, 36.16M → 38.15M (in $), with an average increase of 2.6% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -7.07M → -6.66M (in $), with an average increase of 6.2% per quarter

  • Vs BSX

    In the last 1 year, Boston Scientific Corp. has given 32.4% return, outperforming this stock by 90.5%

  • Vs BSX

    In the last 3 years, Boston Scientific Corp. has given 38.0% return, outperforming this stock by 95.1%

Performance

  • $4.97
    $5.15
    $5.06
    downward going graph

    1.88%

    Downside

    Day's Volatility :3.59%

    Upside

    1.75%

    downward going graph
  • $4.63
    $13.66
    $5.06
    downward going graph

    8.5%

    Downside

    52 Weeks Volatility :66.11%

    Upside

    62.96%

    downward going graph

Returns

PeriodAxogen, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
-44.32%
-1.7%
0.0%
6 Months
-44.38%
1.3%
-0.1%
1 Year
-58.12%
5.1%
5.6%
3 Years
-58.12%
24.3%
17.6%

Highlights

Market Capitalization
214.9M
Book Value
$2.26
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-0.55
PEG Ratio
0.0
Wall Street Target Price
15.0
Profit Margin
-15.86%
Operating Margin TTM
-16.7%
Return On Assets TTM
-7.97%
Return On Equity TTM
-23.6%
Revenue TTM
147.9M
Revenue Per Share TTM
3.48
Quarterly Revenue Growth YOY
10.7%
Gross Profit TTM
114.4M
EBITDA
-21.5M
Diluted Eps TTM
-0.55
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.26
EPS Estimate Next Year
-0.1
EPS Estimate Current Quarter
-0.13
EPS Estimate Next Quarter
-0.09

Analyst Recommendation

Buy
    83%Buy
    16%Hold
    0
    0%Sell
Based on 12 Wall street analysts offering stock ratings for Axogen, Inc.(by analysts ranked 0 to 5 stars)
Based on 12 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
10
10
10
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 196.44%

Current $5.06
Target $15.00

Company Financials

FY17Y/Y Change
Revenue
60.4M
↑ 47.0%
Net Income
-10.4M
↓ 27.52%
Net Profit Margin
-17.29%
↑ 17.77%
FY18Y/Y Change
Revenue
83.9M
↑ 38.91%
Net Income
-22.4M
↑ 114.42%
Net Profit Margin
-26.68%
↓ 9.39%
FY19Y/Y Change
Revenue
106.7M
↑ 27.13%
Net Income
-29.1M
↑ 30.08%
Net Profit Margin
-27.3%
↓ 0.62%
FY20Y/Y Change
Revenue
112.3M
↑ 5.24%
Net Income
-23.8M
↓ 18.36%
Net Profit Margin
-21.18%
↑ 6.12%
FY21Y/Y Change
Revenue
127.4M
↑ 13.41%
Net Income
-27.0M
↑ 13.45%
Net Profit Margin
-21.19%
↓ 0.01%
FY22Y/Y Change
Revenue
138.6M
↑ 8.81%
Net Income
-28.9M
↑ 7.27%
Net Profit Margin
-20.89%
↑ 0.3%
Q1 FY22Q/Q Change
Revenue
31.0M
↓ 1.68%
Net Income
-11.5M
↑ 117.08%
Net Profit Margin
-37.01%
↓ 20.25%
Q2 FY22Q/Q Change
Revenue
34.5M
↑ 11.12%
Net Income
-7.7M
↓ 32.55%
Net Profit Margin
-22.46%
↑ 14.55%
Q3 FY22Q/Q Change
Revenue
37.0M
↑ 7.27%
Net Income
-4.3M
↓ 44.21%
Net Profit Margin
-11.68%
↑ 10.78%
Q4 FY22Q/Q Change
Revenue
36.2M
↓ 2.15%
Net Income
-5.4M
↑ 25.41%
Net Profit Margin
-14.97%
↓ 3.29%
Q1 FY23Q/Q Change
Revenue
36.7M
↑ 1.38%
Net Income
-7.1M
↑ 30.64%
Net Profit Margin
-19.29%
↓ 4.32%
Q2 FY23Q/Q Change
Revenue
38.2M
↑ 4.07%
Net Income
-6.7M
↓ 5.85%
Net Profit Margin
-17.46%
↑ 1.83%
FY17Y/Y Change
Total Assets
58.9M
↑ 26.99%
Total Liabilities
33.7M
↑ 7.17%
FY18Y/Y Change
Total Assets
160.2M
↑ 172.06%
Total Liabilities
13.2M
↓ 60.85%
FY19Y/Y Change
Total Assets
154.6M
↓ 3.45%
Total Liabilities
22.5M
↑ 70.5%
FY20Y/Y Change
Total Assets
201.4M
↑ 30.22%
Total Liabilities
78.2M
↑ 247.85%
FY21Y/Y Change
Total Assets
208.0M
↑ 3.3%
Total Liabilities
95.5M
↑ 22.04%
FY22Y/Y Change
Total Assets
195.5M
↓ 6.01%
Total Liabilities
94.1M
↓ 1.47%
Q1 FY22Q/Q Change
Total Assets
198.0M
↓ 4.81%
Total Liabilities
94.2M
↓ 1.36%
Q2 FY22Q/Q Change
Total Assets
196.1M
↓ 0.98%
Total Liabilities
94.4M
↑ 0.23%
Q3 FY22Q/Q Change
Total Assets
195.5M
↓ 0.29%
Total Liabilities
94.1M
↓ 0.34%
Q4 FY22Q/Q Change
Total Assets
195.4M
↓ 0.07%
Total Liabilities
94.4M
↑ 0.33%
Q1 FY23Q/Q Change
Total Assets
189.5M
↓ 3.03%
Total Liabilities
92.0M
↓ 2.57%
Q2 FY23Q/Q Change
Total Assets
191.6M
↑ 1.14%
Total Liabilities
94.5M
↑ 2.75%
FY17Y/Y Change
Operating Cash Flow
-9.2M
↓ 17.55%
Investing Cash Flow
-1.3M
↑ 8.63%
Financing Cash Flow
17.0M
↑ 3.17%
FY18Y/Y Change
Operating Cash Flow
-17.9M
↑ 93.36%
Investing Cash Flow
-98.2M
↑ 7498.8%
Financing Cash Flow
109.8M
↑ 545.29%
FY19Y/Y Change
Operating Cash Flow
-19.9M
↑ 11.25%
Investing Cash Flow
27.3M
↓ 127.77%
Financing Cash Flow
4.0M
↓ 96.33%
FY20Y/Y Change
Operating Cash Flow
-9.6M
↓ 51.56%
Investing Cash Flow
-17.0M
↓ 162.2%
Financing Cash Flow
40.5M
↑ 904.07%
FY21Y/Y Change
Operating Cash Flow
-13.4M
↑ 39.26%
Investing Cash Flow
-23.6M
↑ 39.42%
Financing Cash Flow
20.5M
↓ 49.47%
FY22Y/Y Change
Operating Cash Flow
-16.1M
↑ 19.85%
Investing Cash Flow
-3.2M
↓ 86.47%
Financing Cash Flow
1.8M
↓ 91.23%
Q1 FY22Q/Q Change
Operating Cash Flow
-11.1M
↑ 629.92%
Investing Cash Flow
-7.2M
↓ 46.7%
Financing Cash Flow
95.0K
↓ 90.89%
Q2 FY22Q/Q Change
Operating Cash Flow
-5.7M
↓ 48.53%
Investing Cash Flow
2.3M
↓ 131.47%
Financing Cash Flow
671.0K
↑ 606.32%
Q3 FY22Q/Q Change
Operating Cash Flow
-689.0K
↓ 87.89%
Investing Cash Flow
3.0M
↑ 30.36%
Financing Cash Flow
215.0K
↓ 67.96%
Q4 FY22Q/Q Change
Operating Cash Flow
1.4M
↓ 297.68%
Investing Cash Flow
-1.2M
↓ 140.69%
Financing Cash Flow
813.0K
↑ 278.14%
Q1 FY23Q/Q Change
Operating Cash Flow
-7.4M
↓ 645.01%
Investing Cash Flow
-786.0K
↓ 34.99%
Financing Cash Flow
633.0K
↓ 22.14%

Technicals Summary

Sell

Neutral

Buy

Axogen, Inc. is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Axogen, Inc.
Axogen, Inc.
-21.75%
-44.38%
-58.12%
-58.12%
-86.26%
Stryker Corporation
Stryker Corporation
-4.23%
-3.92%
29.72%
30.18%
49.2%
Boston Scientific Corp.
Boston Scientific Corp.
-3.14%
7.2%
32.44%
37.98%
33.66%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
-7.79%
-12.9%
-16.37%
-9.78%
23.13%
Abbott Laboratories
Abbott Laboratories
-7.06%
-1.63%
-2.81%
-9.18%
28.89%
Medtronic Plc
Medtronic Plc
-3.89%
-1.62%
-5.29%
-23.83%
-21.38%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Axogen, Inc.
Axogen, Inc.
NA
NA
0.0
-0.26
-0.24
-0.08
0.0
2.26
Stryker Corporation
Stryker Corporation
37.65
37.65
2.85
10.36
0.16
0.06
0.01
45.71
Boston Scientific Corp.
Boston Scientific Corp.
89.54
89.54
2.53
2.0
0.05
0.04
0.0
12.46
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
31.28
31.28
3.07
2.55
0.22
0.12
0.0
10.49
Abbott Laboratories
Abbott Laboratories
32.84
32.84
18.76
4.39
0.14
0.06
0.02
21.42
Medtronic Plc
Medtronic Plc
29.13
29.13
3.04
5.28
0.07
0.04
0.03
38.47
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Axogen, Inc.
Axogen, Inc.
Buy
$214.9M
-86.26%
NA
-15.86%
Stryker Corporation
Stryker Corporation
Buy
$101.2B
49.2%
37.65
13.92%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$77.4B
33.66%
89.54
6.81%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
Buy
$42.8B
23.13%
31.28
24.56%
Abbott Laboratories
Abbott Laboratories
Buy
$167.0B
28.89%
32.84
12.83%
Medtronic Plc
Medtronic Plc
Buy
$105.0B
-21.38%
29.13
11.47%

Institutional Holdings

  • ArrowMark Colorado Holdings, LLC (ArrowMark Partners)

    9.12%

  • BlackRock Inc

    7.66%

  • Vanguard Group Inc

    5.63%

  • First Light Asset Management, LLC

    4.59%

  • Bank of America Corp

    4.19%

  • Soleus Capital Management, L.P.

    4.16%

Corporate Announcements

  • Axogen, Inc. Earnings

    Axogen, Inc.’s price-to-earnings ratio stands at None

    Read More

Company Information

it's time to rethink nerve repair! axogen (nasdaq: axgn) is a medical products company with a portfolio of proprietary products and technologies for peripheral nerve reconstruction and regeneration. people suffer traumatic injuries or undergo surgeries that impact the function of their peripheral nerves daily. damage may cause loss of function and feeling. axogen is bringing the science of nerve repair to life with its avance® nerve graft which axogen believes is the first and only commercially available allograft for bridging nerve discontinuities, axoguard® nerve connector, a coaptation aid allowing for close approximation of severed nerves, and axoguard® nerve protector that protects nerves during the healing process.

Organization
Axogen, Inc.
Employees
394
CEO
Ms. Karen Zaderej
Industry
Health Technology

Discover More

FAQs